ADMA Biologics Inc $ADMA Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lessened its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 8.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,790,518 shares of the biotechnology company’s stock after selling 351,322 shares during the quarter. Thrivent Financial for Lutherans’ holdings in ADMA Biologics were worth $69,139,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Morse Asset Management Inc acquired a new position in ADMA Biologics in the fourth quarter worth $44,000. Truist Financial Corp acquired a new position in ADMA Biologics in the fourth quarter worth $204,000. Nkcfo LLC acquired a new position in ADMA Biologics in the fourth quarter worth $47,000. Mitsubishi UFJ Trust & Banking Corp boosted its holdings in ADMA Biologics by 29.0% in the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 19,342 shares of the biotechnology company’s stock worth $353,000 after purchasing an additional 4,346 shares during the period. Finally, Ashton Thomas Private Wealth LLC acquired a new position in ADMA Biologics in the fourth quarter worth $209,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Buying and Selling at ADMA Biologics

In related news, Director Jerrold B. Grossman acquired 12,500 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the purchase, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the sale, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. This represents a 2.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.90% of the stock is currently owned by company insiders.

ADMA Biologics Stock Performance

ADMA stock opened at $8.27 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of 12.16 and a beta of 0.83. ADMA Biologics Inc has a 1 year low of $7.21 and a 1 year high of $22.37. The stock’s fifty day moving average is $11.20 and its two-hundred day moving average is $15.19.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.19. The company had revenue of $114.49 million for the quarter, compared to analysts’ expectations of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The firm’s quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the business posted $0.11 earnings per share. On average, research analysts predict that ADMA Biologics Inc will post 0.84 EPS for the current year.

Analyst Upgrades and Downgrades

ADMA has been the subject of a number of research reports. Zacks Research downgraded shares of ADMA Biologics from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Canaccord Genuity Group cut their target price on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Wall Street Zen cut ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Finally, Mizuho cut their target price on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, ADMA Biologics presently has a consensus rating of “Hold” and a consensus target price of $19.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.